Geovax Labs Inc Stock Price, News & Analysis

GeoVax Labs, Inc. (Nasdaq: GOVX) will report its 2022 financial results on March 23, 2023, after market close. The announcement will be followed by a live conference call at 4:30 PM ET, providing a general business update and financial discussion. Investors and analysts can join the call via domestic and international numbers or through a provided webcast link. GeoVax is developing innovative vaccines and immunotherapies for cancer and infectious diseases, including a next-generation COVID-19 vaccine, GEO-CM04S1, currently in two Phase 2 trials targeting high-risk populations.

GeoVax Labs (Nasdaq: GOVX) has announced that its Chairman and CEO, David Dodd, will discuss the company's advancements during a fireside chat at the 35th Annual Roth Conference on March 14, 2023, at 12:30 PM PT. The discussion, led by Senior Research Analyst Kumaragura Raja, Ph.D. from ROTH MKM, will focus on GeoVax's progress in developing immunotherapies and vaccines against cancers and infectious diseases. The company is conducting Phase 1/2 trials for its Gedeptin® therapy and Phase 2 trials for its next-generation COVID-19 vaccine, GEO-CM04S1. Investors can view the webcast of the event here.

GeoVax Labs has presented promising clinical trial results for its HIV vaccine candidate, MVA62B, at the Conference on Retroviruses and Opportunistic Infections held in Seattle. The trial, led by UCSF researchers, focuses on a combinational therapy aimed at achieving a functional cure for HIV, demonstrating high immunogenicity and enhanced T cell responses. The findings suggest potential efficacy in reducing viral replication without traditional antiviral medications. The company continues its commitment to developing immunotherapies for various viral diseases, including COVID-19 and others.

GeoVax Labs, Inc. (GOVX) has announced a collaboration with EmVenio Research to deploy a mobile clinical facility in Claremont, California, to enhance patient recruitment for its ongoing Phase 2 trial of the GEO-CM04S1 COVID-19 booster vaccine. This initiative aims to facilitate access to clinical trials for diverse populations, with a focus on evaluating the vaccine's safety and immunogenicity in healthy patients. GEO-CM04S1 is targeting individuals who have previously received FDA-approved mRNA vaccines. The trial will measure immune responses, including neutralizing antibodies and T-cell responses, to assess its effectiveness against COVID-19.

GeoVax Labs, a biotechnology firm, announced progress in developing a continuous avian cell line system for its MVA-based vaccines and immunotherapies. This new manufacturing method aims to improve efficiency and reduce costs, transitioning from the traditional chicken embryonic fibroblast process. CEO David Dodd emphasized that this transformation will enable timely global responses to health threats and broaden MVA applications. Currently, GeoVax is engaged in clinical trials for its COVID-19 vaccine targeting high-risk populations. The company aims to lead in MVA-based vaccine production, including for diseases like Mpox and Smallpox.

GeoVax Labs (Nasdaq: GOVX) has announced that its Phase 1/2 clinical trial for Gedeptin®, aimed at treating recurrent head and neck cancers, is now actively enrolling patients at Stanford, Emory, and Thomas Jefferson Universities. The trial evaluates the safety and efficacy of Gedeptin with up to five treatment cycles involving intra-tumoral injections. Preliminary results from a prior study indicated that Gedeptin was well-tolerated and showed tumor size reduction. The FDA has granted Gedeptin orphan drug status, which may facilitate further investigations and collaboration in cancer treatment.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference in New York City and virtually from February 6-9, 2023. Dodd's live presentation is scheduled for February 7 at 3:45 PM EST, with an on-demand video also available. The company will hold one-on-one meetings to discuss their innovative therapies and vaccines for cancers and infectious diseases, including the novel COVID-19 vaccine GEO-CM04S1, currently in Phase 2 trials. Interested parties can schedule meetings through the conference page or contact Investor Relations.

GeoVax Labs, Inc. (GOVX) announced a significant achievement in its Zika vaccine development, receiving a Notice of Allowance for its patent application related to its novel vaccine candidate, GEO-ZM02. Preclinical studies showed that a single dose of this vaccine provided 100% protection against a lethal dose of the Zika virus. This promising outcome highlights the vaccine's potential to protect vulnerable populations, particularly women of childbearing age and newborns, against Zika-related diseases. Additionally, GeoVax is advancing its MVA-based next-generation COVID-19 vaccine, currently in Phase 2 trials, further solidifying its commitment to addressing critical infectious diseases.